Kiniksa Pharmaceuticals International (KNSA) EPS (Weighted Average and Diluted) (2019 - 2026)

Kiniksa Pharmaceuticals International has reported EPS (Weighted Average and Diluted) for 8 years, with the latest figure at $0.27 in Q1 2026.

• For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 145.45% year-over-year to $0.27; the trailing twelve-month figure through Mar 2026 stood at $0.91 (up 464.0% YoY), and the FY2025 full-year result was $0.75, up 225.0% from the prior year.
• EPS (Weighted Average and Diluted) for Q1 2026 stood at $0.27, up from $0.18 in the prior quarter.
• The five-year high for EPS (Weighted Average and Diluted) was $3.18 in Q3 2022, with the low at -$0.36 in Q1 2022.
• Historically, EPS (Weighted Average and Diluted) has averaged $0.19 across 5 years, with a median of $0.05 in 2022.
• Annual changes were most pronounced in 2022 — EPS (Weighted Average and Diluted) soared 822.73% — and 2024, when it tumbled 133.33%.
• Kiniksa Pharmaceuticals International's EPS (Weighted Average and Diluted) stood at $0.05 in 2022, then jumped by 620.0% to $0.36 in 2023, then sank by 133.33% to -$0.12 in 2024, then jumped by 250.0% to $0.18 in 2025, then soared by 50.0% to $0.27 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.27 (Q1 2026), $0.18 (Q4 2025), and $0.23 (Q3 2025), per Business Quant data.